Elevated Rate Pacing of Cardiac Amyloidosis

University of Minnesota (UMN)

Status: Enrolling

Conditions: Cardiac Amyloidosis; Pacemaker

Treatments: Other: Pacemaker Rate

Study type: Interventional

Funder types: Other

Identifiers

NCT07583823

CV-2025-33753

Details and patient eligibility

About

This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.

Enrollment: 10 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults 18 and older
• Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee
• Implanted Cardiac Pacemaker (+/- Defibrillator)
• Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation
• Non-dilated left ventricle by echocardiography
• Ability to provide written consent
• English Speaking

Exclusion criteria

• Paced QRS duration of >150 ms (indicator for pacing mediated dyssynchrony)
• Dilated left ventricle

Trial design

Primary purpose: Supportive Care

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Elevated Pacemaker Rate

Experimental group

Description:

CA clinic patients with pacemakers will receive a personalized pacing protocol individual to their height and left ventricular ejection fraction.

Treatment:

Other: Pacemaker Rate